Phase 3Status unknown
The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
Comparison of Efficacy and Safety of Icaritin Versus Cinobufotalin in First-line Treatment of Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Double-blind, Double-dummy Phase III Clinical Trial
- Sponsor
- Beijing Shenogen Biomedical Co., Ltd (Industry)
- Enrolment
- 312 planned
- Conditions
- Advanced HBV-Related Hepatocellular Carcinoma (HCC)
- Interventions
- Icaritin; HUACHANSU PIAN
- Ages
- adults, older adults
- Registry
- NCT03236636
Full record on ClinicalTrials.gov
From the registry
The enriched HBV-related advanced HCC patient population (composite biomarker score ≥ 2) and overall survival (OS) were compared between the two groups.
Primary outcomes
- Overall survival (OS)
History
Primary completion
Last registry update
Started
Registered